PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24885948-0	2014	Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway.	Sorafenib	22-31	mitogen activated protein kinase 3	Rattus norvegicus	126-132	
25367879-5	2015	In addition, BAY 43-9006 treatment significantly reversed the phosphorylation of ERK1/2 and the activation of NF-kappaB induced by SAH and decreased the messenger RNA (mRNA) levels of IL-6 and IL-1beta.	Sorafenib	13-24	mitogen activated protein kinase 3	Rattus norvegicus	81-87	
25367879-7	2015	Besides, BAY 43-9006 inhibited the phosphorylation of Raf-1 and ERK1/2; decreased the protein levels of COX-2, VEGF, and MMP-9; and reversed the activation of NF-kappaB induced by SAH.	Sorafenib	9-20	mitogen activated protein kinase 3	Rattus norvegicus	64-70	
24885948-8	2014	CONCLUSION: We show that sorafenib exhibits a regulatory role on the occurrence of LVH following AB in rats by blocking the rise in growth factors PDGF-BB and TGFbeta1, activation of the corresponding c-Raf-ERK1/2 signaling pathway and effector mechanisms, including GATA4 and ANP.	Sorafenib	25-34	mitogen activated protein kinase 3	Rattus norvegicus	207-213	
18955668-8	2008	Sorafenib prevented phosphorylation of Raf-1 and suppressed activation of the downstream ERK1/2 signaling pathway in RV myocardium and the lungs.	Sorafenib	0-9	mitogen activated protein kinase 3	Rattus norvegicus	89-95